At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
CK-3773274 (5 - 15 mg) +2 moredrug
Likely dose
CK-3773274 (5 - 15 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy
In Brief
A Phase 2 clinical trial evaluating CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), and 1 other intervention for Hypertrophic Cardiomyopathy (HCM). Completed, enrolled 96 participants across 22 sites in 4 countries.
Detailed Summary
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertrophic Cardiomyopathy (HCM)
CountriesItaly, Netherlands, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartJan 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedJan 7, 2020
Enrollment StartJan 10, 2020
Primary CompletionFeb 28, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.5 years ago
Interventions
CK-3773274 (5 - 15 mg)drug
CK-3773274 tablets administered orally once daily
CK-3773274 (10 - 30 mg)drug
CK-3773274 tablets administered orally once daily
Placebo for CK-3773274drug
Placebo administered orally once daily